Mauritius Telecom and Aprecomm Come Together to Bring Innovation to Customer Experience With Network Intelligence
Mauritius Telecom, the largest ISP in Mauritius with cellular and high-speed broadband service distribution, today announced its intent to bring Artificial Intelligence based innovative technology to enhance visibility and optimize its residential Wi-Fi connections through a partnership with Aprecomm. This A.I. technology will help Mauritius Telecom to bring proactive Network Intelligence transformation to improve customer experience and to drastically reduce the time for resolution of customer-end issues across their broadband network covering more than 300,000 households.
Speaking on the development, Mr. Kapil Reesaul, CEO, Mauritius Telecom, said, “Mauritius Telecom is the forefront runner in continuous investments in technology to keep innovating and providing the best service to its consumers. The partnership with Aprecomm will help us in our efforts to ensure the best experience across our broadband consumers with faster and proactive resolution of potential issues.”
Pramod Gummaraj, CEO, Aprecomm, said, “We're excited to team up with Mauritius Telecom and implement cutting-edge technology into their network in order to help them cut down on support ticket response times by as much as half and provide a dramatically better experience for their customers. Network Innovation focused on customer experience could be deployed across in the coming months.”
The measurable improvements offered by the integration between Mauritius Telecom and Aprecomm also lead to lower maintenance cost and improved customer satisfaction for one of the country’s fastest growing ISPs.
“With Aprecomm’s vendor agnostic technology, Mauritius Telecom will be able to manage and monitor Network Elements through a unified interface, ensuring assured internet experience to their customers,” said Guharajan Sivakumar, CTO, Aprecomm.
“Network Automation will allow us to bring the best possible experience to our end customers. Measurable customer experience and proactive actions to improve it will be part of this partnership as Aprecomm technology is aligned towards Network Automation,” said Mr. Yagianath Rosunee, CTO of Mauritius Telecom.
About Mauritius Telecom
Mauritius Telecom is the leading provider of an extensive range of ICT services and solutions for both residential customers and businesses in Mauritius, including fixed, mobile, broadband, TV, mobile money and ICT services. Mauritius Telecom has played a pivotal role in the socio-economic development of Mauritius, paving the way for the growth of the ICT industry, which has become a major pillar of the Mauritian economy. Mauritius Telecom has taken bold initiatives to transform the lives of Mauritians, deploying fibre island-wide to provide ultra-high-speed broadband to all, disrupting the payment landscape with a mobile wallet thus revolutionizing payments in Mauritius, launching in 2021 the first 5G Experience Zones and the first 1Gbps fibre internet to home offer in Mauritius. In 2022 Mauritius Telecom’s mobile service, my.t mobile reached the milestone of one million customers.
- Headquarters: Port Louis, Mauritius
- Website: https://www.telecom.mu, https://www.myt.mu/
- LinkedIn: https://www.linkedin.com/company/mauritius-telecom/
- Facebook: https://www.facebook.com/mauritiustelecom
About Aprecomm
Aprecomm is an industry game-changer with a Network Intelligence Software Stack to understand Customer Experience. Aprecomm offers cloud-based automated solutions to enhance Wired and Wi-Fi network performance. Aprecomm’s patented technology helps in automatically and proactively troubleshooting Wi-Fi issues. This way ISPs and Enterprises will be able to fix them immediately and dramatically minimize down-time. Aprecomm’s solutions help enterprises, ISPs, TSPs improve their business standards through higher reliability, reduced expenses, and speedy ROI.
- Headquarters: Bangalore, India
- Website: https://aprecomm.ai
- LinkedIn: https://in.linkedin.com/company/aprecomm
- Facebook: https://www.facebook.com/aprecomm/
- Twitter: https://twitter.com/aprecomm_ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005801/en/
Contact information
For further details please contact:
Aprecomm
Shankar Peerthy
Email: Peerthy@aprecomm.ai
Contact: +41-78 685 82 58
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom